215. Tetralogy of Fallot Clinical trials / Disease details
Clinical trials : 18 / Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04017975 (ClinicalTrials.gov) | December 20, 2019 | 10/7/2019 | Optical Tissue Identification for Myocardial Architecture | Optical Tissue Identification for Myocardial Architecture (OPTIMA Study) | Ventricular Septal Defect;Complete Atrioventricular Canal;Tetralogy of Fallot With Pulmonary Stenosis | Drug: Fluorescite;Device: Cellvizio 100 Series System with Confocal Miniprobes | Aditya Kaza | National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting | 30 Days | 18 Years | All | 70 | Phase 2 | United States |